Cargando…

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension

AIMS: Patients with heart failure (HF) exhibit poor prognosis, which is further deteriorated by pulmonary hypertension (PH), with negative impact on morbidity and mortality. As PH due to left HF (LHF‐PH) is among the most common causes of PH, there is an urge according to the 2021 European Society o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engel Sällberg, Adam, Helleberg, Sara, Ahmed, Salaheldin, Ahmed, Abdulla, Rådegran, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682849/ https://www.ncbi.nlm.nih.gov/pubmed/37772417 http://dx.doi.org/10.1002/ehf2.14507

Ejemplares similares

Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
por: Ahmed, Salaheldin, et al.
Publicado: (2021)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
por: Kania, Kriss, et al.
Publicado: (2022)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
por: Ahmed, Salaheldin, et al.
Publicado: (2020)

Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2020)

Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics
por: Ahmed, Salaheldin, et al.
Publicado: (2020)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Plasma Biomarkers for Clinical Assessment of Bone Mineral Density in Heart Transplanted Patients—A Single-Center Study at Skåne University Hospital in Lund
por: Löfdahl, Eveline, et al.
Publicado: (2022)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Prolargin and matrix metalloproteinase‐2 in heart failure after heart transplantation and their association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2019)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation
por: Lundgren, Jakob, et al.
Publicado: (2015)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2018)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2019)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Effect of Exercise Training on Interleukin-6, Tumour Necrosis Factor Alpha and Functional Capacity in Heart Failure
por: Smart, Neil A., et al.
Publicado: (2011)

Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction
por: Sandqvist, Anna, et al.
Publicado: (2017)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Quality of life and functional status after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: A Swedish single‐center study
por: Kallonen, Janica, et al.
Publicado: (2023)

Deranged Lung Perfusion Pattern in Patients With Heart Failure Normalizes After Heart Transplantation
por: Al-Mashat, Mariam, et al.
Publicado: (2020)

Increased biventricular hemodynamic forces in precapillary pulmonary hypertension
por: Pola, Karin, et al.
Publicado: (2022)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se
por: Lindholm, Anthony, et al.
Publicado: (2019)

Underfilling decreases left ventricular function in pulmonary arterial hypertension
por: Sjögren, Hannah, et al.
Publicado: (2021)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Longitudinal changes in risk status in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2020)

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre‐capillary pulmonary hypertension
por: Bredfelt, Anna, et al.
Publicado: (2018)

Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension
por: Lindholm, Anthony, et al.
Publicado: (2022)

Pulmonary Hypertension in Heart Failure
por: Jang, Albert Youngwoo, et al.
Publicado: (2021)

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016
por: Kjellström, Barbro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l6c4qpcnv7pvmk31smr0vd3ojl